437 related articles for article (PubMed ID: 31717860)
1. The Role of Gut-Derived Microbial Antigens on Liver Fibrosis Initiation and Progression.
Chen D; Le TH; Shahidipour H; Read SA; Ahlenstiel G
Cells; 2019 Oct; 8(11):. PubMed ID: 31717860
[TBL] [Abstract][Full Text] [Related]
2. Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease.
Katsarou A; Moustakas II; Pyrina I; Lembessis P; Koutsilieris M; Chatzigeorgiou A
World J Gastroenterol; 2020 May; 26(17):1993-2011. PubMed ID: 32536770
[TBL] [Abstract][Full Text] [Related]
3. Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders.
Chopyk DM; Grakoui A
Gastroenterology; 2020 Sep; 159(3):849-863. PubMed ID: 32569766
[TBL] [Abstract][Full Text] [Related]
4. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
[TBL] [Abstract][Full Text] [Related]
5. Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation.
Nicoletti A; Ponziani FR; Biolato M; Valenza V; Marrone G; Sganga G; Gasbarrini A; Miele L; Grieco A
World J Gastroenterol; 2019 Sep; 25(33):4814-4834. PubMed ID: 31543676
[TBL] [Abstract][Full Text] [Related]
6. Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics.
Nagashimada M; Honda M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360773
[TBL] [Abstract][Full Text] [Related]
7. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
8. Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies.
Frasinariu OE; Ceccarelli S; Alisi A; Moraru E; Nobili V
Dig Liver Dis; 2013 Jul; 45(7):543-51. PubMed ID: 23280158
[TBL] [Abstract][Full Text] [Related]
9. Role of Kupffer Cells in Driving Hepatic Inflammation and Fibrosis in HIV Infection.
Zhang L; Bansal MB
Front Immunol; 2020; 11():1086. PubMed ID: 32612603
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Probiotics (MCP
Mohamad Nor MH; Ayob N; Mokhtar NM; Raja Ali RA; Tan GC; Wong Z; Shafiee NH; Wong YP; Mustangin M; Nawawi KNM
Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579068
[TBL] [Abstract][Full Text] [Related]
11. Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease.
Bibbò S; Ianiro G; Dore MP; Simonelli C; Newton EE; Cammarota G
Mediators Inflamm; 2018; 2018():9321643. PubMed ID: 29563854
[TBL] [Abstract][Full Text] [Related]
12. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
Arab JP; Martin-Mateos RM; Shah VH
Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
[TBL] [Abstract][Full Text] [Related]
13. Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD.
Pierantonelli I; Rychlicki C; Agostinelli L; Giordano DM; Gaggini M; Fraumene C; Saponaro C; Manghina V; Sartini L; Mingarelli E; Pinto C; Buzzigoli E; Trozzi L; Giordano A; Marzioni M; Minicis S; Uzzau S; Cinti S; Gastaldelli A; Svegliati-Baroni G
Sci Rep; 2017 Sep; 7(1):12200. PubMed ID: 28939830
[TBL] [Abstract][Full Text] [Related]
14. Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C.
Tanwar S; Rhodes F; Srivastava A; Trembling PM; Rosenberg WM
World J Gastroenterol; 2020 Jan; 26(2):109-133. PubMed ID: 31969775
[TBL] [Abstract][Full Text] [Related]
15. Gut-liver axis signaling in portal hypertension.
Simbrunner B; Mandorfer M; Trauner M; Reiberger T
World J Gastroenterol; 2019 Oct; 25(39):5897-5917. PubMed ID: 31660028
[TBL] [Abstract][Full Text] [Related]
16. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut.
Seki E; Schnabl B
J Physiol; 2012 Feb; 590(3):447-58. PubMed ID: 22124143
[TBL] [Abstract][Full Text] [Related]
17. Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis.
Maslennikov R; Poluektova E; Zolnikova O; Sedova A; Kurbatova A; Shulpekova Y; Dzhakhaya N; Kardasheva S; Nadinskaia M; Bueverova E; Nechaev V; Karchevskaya A; Ivashkin V
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003692
[TBL] [Abstract][Full Text] [Related]
18. Intestinal Immune Dysregulation Driven by Dysbiosis Promotes Barrier Disruption and Bacterial Translocation in Rats With Cirrhosis.
Muñoz L; Borrero MJ; Úbeda M; Conde E; Del Campo R; Rodríguez-Serrano M; Lario M; Sánchez-Díaz AM; Pastor O; Díaz D; García-Bermejo L; Monserrat J; Álvarez-Mon M; Albillos A
Hepatology; 2019 Sep; 70(3):925-938. PubMed ID: 30414342
[TBL] [Abstract][Full Text] [Related]
19. Monocyte-macrophage activation is associated with nonalcoholic fatty liver disease and liver fibrosis in HIV monoinfection independently of the gut microbiome and bacterial translocation.
Maurice JB; Garvey L; Tsochatzis EA; Wiltshire M; Cooke G; Guppy N; McDonald J; Marchesi J; Nelson M; Kelleher P; Goldin R; Thursz M; Lemoine M
AIDS; 2019 Apr; 33(5):805-814. PubMed ID: 30882489
[TBL] [Abstract][Full Text] [Related]
20. Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model.
Douhara A; Moriya K; Yoshiji H; Noguchi R; Namisaki T; Kitade M; Kaji K; Aihara Y; Nishimura N; Takeda K; Okura Y; Kawaratani H; Fukui H
Mol Med Rep; 2015 Mar; 11(3):1693-700. PubMed ID: 25421042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
